New drug targets genetic weakness in mesothelioma tumors

NCT ID NCT07602946

Not yet recruiting Disease control Sponsor: University of Southampton Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called BMS-986504 in 30 people with relapsed mesothelioma whose tumors have a specific genetic marker (MTAP deficiency). The drug aims to shrink tumors by blocking a protein cancer cells need to grow. Researchers will measure how many patients have their disease controlled at 12 and 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986504 (a targeted drug that blocks a protein called PRMT5, aiming to stop cancer cell growth)
What this could lead to: If it works, this could provide a new targeted treatment option for people with a specific genetic type of relapsed mesothelioma, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is an early phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA

Contacts and locations

Locations

Leicester Royal Infirmary

Leicester, , LE1 5WW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.